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Abstract: Periodontal disease is considered one of the main pathologic diseases occurring in humans.
Its pathologic process involves inflammatory reactions producing periodontal bone resorption and
the tooth loss. But some patients do not present an evident clinical inflammation with bone resorption,
and in others, the inflammation is prominent without bone resorption. A key question could be to
investigate a different way of responding to aggression. Inflammation requires a complex intracellular
metabolic process, starting with the harmful recognition and activation of the inflammasome,
continues the energy supply with the alteration of oxidative stress conditions, and finishes with
the elimination of the aggression with autophagy/apoptosis mechanisms, then concludes with
recovery. Peroxisome proliferator-activated receptors (PPARs) are essential molecules produced
in inflammation, and its genes and its activation have been related to periodontal disease. Also,
an important aspect is the influence of PPARs in bone metabolism; the main periodontitis symptom
is bone loss and PPARγ activation that can downregulate the bone resorption in experimental
periodontitis, PPARγ-coated titanium dental implant surfaces could carry the antiinflammatory
gene and restrain inflammation. PPARs could be one of the meeting background points with
atherosclerosis/cardiovascular disease, diabetes and metabolic syndrome showing a modified
proinflammatory statement such as it is described in periodontitis.
Keywords: periodontitis; inflammasome; mitochondria; autophagy; atherosclerosis; diabetes;
metabolic syndrome
1. Introduction
Plaque-induced periodontal diseases are mixed infections which cause inflammation in the tissues
around the teeth; this site is known as the periodontium and compromises all of its components.
We divided it into two general categories based on whether illness to periodontium is reversible or not.
So, respectively, we can differentiate between gingivitis and periodontitis [1].
Gingivitis supposes the presence of gingival inflammation without loss of gingival attachment;
the site affected is limited to the gingiva. On the other hand, periodontitis is an inflammatory disease
of the periodontal tissues with a more complex pathogenic process. Main symptoms in periodontitis
are an apical migration of gingival attachment, a progressive periodontal bone loss and the formation
of a periodontal pocket. The endpoint in the progression of this process is the tooth loss. This disease
does not compromise the life of the patient, but produces a decrease in their quality of life. Severe
periodontitis may result in discomfort for the patient, tooth mobility, abscess formation, occasional
pain, difficulty in chewing and finally, tooth loss [2] (Figure 1).
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Figure 1. (a) Healthy periodontium: gingiva (G), periodontal ligament (L), root cementum (C) and 
alveolar bone (B); (b) Gingivitis; there is presence of calculus (DC). The inflammation is reversible; 
and (c) Severe form of chronic periodontitis: gingival inflammation, depth pocket, subgingival 
calculus and mobility. 
Nowadays, periodontal diseases take real importance in our society on account of their high 
prevalence. The prevalence of gingivitis is over 80% with the peak being reached during puberty [3]. 
Chronic periodontitis affects about 50% of the European population, and over 10% may suffer from 
an aggressive form, with this prevalence increasing up to 70–85% at 60–65 years of age [4]. Also, it is 
expected that this prevalence data is maintaining during the next decade in Europe [5]. Therefore, 
periodontal diseases are considered one of the most common diseases. 
The key questions are the etiological and pathogenic processes involved, but many aspects are 
still unclear. Authors try to explain why in some patients, the disease produced by bacterial infection 
is limited to the gingiva and in others ones produces bone loss, and also the degree of bone resorption 
could be more or less severe, and even in aggressive periodontitis a lack of plaque and inflammation 
is described. 
To explain it, researches have been focused on individual factors like the host response or 
microbial infection. Traditionally, the main cause of periodontal diseases is attributed to some 
bacterial species that colonize subgingival sites or pockets, which are the responsible for the 
inflammatory reaction. Nowadays, our treatment consists of reducing and eliminating the 
subgingival microorganisms. But, we have to recognize some significant limitations: we do not obtain 
success in all the patients, prevention is not feasible, we do not have any ways to identify the 
susceptible population, and a complete regeneration of periodontal tissues is presently impracticable. 
Besides, plaque is not essential in aggressive forms of periodontitis, and the control of the periodontal 
disease becomes more difficult [6]. Certain microorganisms are related with the pathogenesis of 
periodontal disease, but the evidence does not support the invasion of a periodontal pathogen as a 
key step in this process [7]. Therefore, periodontitis is produced by an imbalance among 
microbiota/dental biofilm and the inflammatory response that have to play a key role. 
Inflammation is the main common backgrounds, with others systemic diseases such as 
atherosclerosis and atherosclerosis, diabetes and metabolic syndrome. These have been correlated 
with periodontitis in epidemiological studies. But, while periodontitis does not kill people, these 
others pathologies jeopardize the life of patients and are the main causes of death in our countries. 
All have a complex etiology, with a combination of non-modifiable risk factors (age or genetic), and 
modifiable risk factors: tobacco, alcohol, malnutrition, and chronic infection [8]. 
Inflammation is a physiological response to stress which involves a multitude of processes. 
Firstly, it is necessary that innate immune system recognizes the aggression made by 
microorganisms, toxins and chemical compounds. These are identified as the pathogen-associated 
molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) that are recognized 
via the pattern recognition receptors (PRRs) [9]. The cytoplasmic PAMPs and endogenous DAMPs 
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an aggressive for , with this prevalence increasing up to 70–85% at 60–65 years of age [4]. Also, it is
expected that this prevalence data is aintaining during the next decade in Europe [5]. Therefore,
periodontal diseases are considered one of the most common diseases.
The key questions are the etiological and pathogenic processes involved, but any aspects are
still unclear. Authors try to explain hy in so e patients, the disease produced by bacterial infection
is li ited to the gingiva and in others ones produces bone loss, and also the degree of bone resorption
could be ore or less severe, and even in aggressive periodontitis a lack of plaque and infla ation
is described.
To explain it, researches have been focused on individual factors like the host response or microbial
infection. Traditionally, the main cause of periodontal diseases is attributed to some bacterial species
that colonize subgingival sites or pockets, which are the responsible for the inflammatory reaction.
Nowadays, our treatment consists of reducing and eliminating the subgingival microorganisms.
But, we have to recognize some significant limitations: we do not obtain success in all the patients,
prevention is not feasible, we do not have any ways to identify the susceptible population, and
a complete regeneration of periodontal tissues is presently impracticable. Besides, plaque is not
essential in aggressive forms of periodontitis, and the control of the periodontal disease becomes more
difficult [6]. Certain microorganisms are related with the pathogenesis of periodontal disease, but the
evidence does not support the invasion of a periodontal pathogen as a key step in this process [7].
Therefore, periodontitis is produced by an imbalance among microbiota/dental biofilm and the
inflammatory response that have to play a key role.
Infla ation is the main common backgrounds, with others syste ic diseases such as
atherosclerosis and atherosclerosis, diabetes and metabolic syndrome. These have been correlated with
periodontitis in epidemiological studies. But, while periodontitis does not kill people, these others
pathologies jeopardize the life of patients and are the main causes of death in our countries. All have a
complex etiology, with a combination of non-modifiable risk factors (age or genetic), and modifiable
risk factors: tobacco, alcohol, malnutrition, and chronic infection [8].
Inflammation is a physiological response to stress which involves a multitude of processes.
Firstly, it is necessary that innate immune system recognizes the aggression made by microorganisms,
toxins and chemical compounds. These are identified as the pathogen-associated molecular patterns
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(PAMPs) or danger-associated molecular patterns (DAMPs) that are recognized via the pattern
recognition receptors (PRRs) [9]. The cytoplasmic PAMPs and endogenous DAMPs activate PRRs and
induce an intracellular signaling leading to the activation of inflammasome-driven inflammation [10].
Inflammasomes are large multiprotein complexes localized in the cytoplasm of the cell; it is essential
in initiating innate immune responses. They produce the maturation of pro-inflammatory cytokines
and the activation of inflammatory cell death [11]. Several inflammasomes are well-characterized for
their role in recognition of PAMPs and DAMPs such as NLRP3 (nucleotide-binding leucine-rich repeat
containing family, pyrin domain containing 3) [12]. Inflammasome activity is central to appropriate
host defense and protection from sepsis, but excessive inflammasome activation could be detrimental
to health [13].
Secondly, to maintain this inflammatory reaction, a sufficient supply of energy obtained from
nutrients of the diet is necessary. But nowadays, humans have an excessive offer of nutrients that
produce metabolic disorders. In the origin of these is a “proinflammatory” state produced by excessive
caloric intake and over-nutrition and other innate conditions related with inflammation [14]. These
nutrients are metabolized via the Krebs cycle, fatty-acid oxidation and amino acid oxidation to obtain
adenosine 5´-triphosphate (ATP). This ATP is the fuel in cells of living organisms and the mitochondrion
is the major source of ATP via cell respiration [15]. During respiration, oxygen is used to oxidize
molecules rich in carbon and hydrogen, and a reduction of oxygen to water. This reaction realizes free
radicals and/or reactive oxygen species (ROS); both are capable of damage different substrates. The
antioxidants are responsible for preventing the oxidative damage, but any defect in the respiratory
chain, mitochondrial diseases and age could alter this balance and produce oxidative stress [16]. Also,
we cannot forget free radicals and ROS are essential in the physiological processes, but when an
antioxidant system is unable to counteract their action efficiently, tissue and cell damage result [17].
So, the role of oxidative stress is essential in the mechanisms of inflammatory condition [14].
Finally, to maintain and control inflammation, cells need to function properly. The degradation of
organelles and the elimination of invading pathogens are essential for the cell’s homeostasis. In this
sense, one of the main catabolic pathways is autophagy. Autophagy allows for an appropriate response
to stress and extrinsic or intrinsic insults [18]. Impaired autophagy produce various pathologies,
including cardiovascular disease and periodontitis [19,20], and is directly related to a regulatory role
for ROS originated in mitochondria [21]. When autophagy is blocked, this leads to activation the NLRP3
inflammasome, which explains the frequent association of mitochondrial damage with inflammatory
diseases [22]. Additionally, autophagy is regulated by the mammalian target of rapamycin (mTOR),
which shuts off autophagy in the presence of growth factors and abundant nutrients [23]. In vitro
surveys suggest that periodontal pathogens can induce mTOR degradation in epithelial cells [24].
Furthermore, the mTOR activates peroxisome proliferator-activated receptors (PPARs) [25], which have
been increasingly recognized as key players in the pathogeneses of metabolic diseases and primary
metabolic regulators [26]. In addition, PPARs are in direct relation with the NLRP3 inflammasome [27].
It is well-known that periodontitis shares pathological features with the mentioned systemic
pathologies [7]. The evidence appears to indicate that the common link between periodontitis and
systemic diseases seems to be inflammation [9]. Although inflammation is a protective physiological
response, it can sometimes lead to the destruction of tissue, starting a disease. There are a multitude of
molecular routes related with inflammation which have been studied to explain the physiopathological
processes taking place place in periodontitis. Routes related with inflammasomes and autophagy
have been widely investigated [9,19]. Also, there is evidence for a decreased antioxidant capacity
and mitochondrial dysfunction in patients with periodontitis [28,29]. In fact, animals studies have
shown that antioxidant treatment with coenzyme Q is able to reduce the progression of alveolar bone
destruction [30].
Nowadays, the key questions in periodontitis remain unanswered. Why in some patients does
the inflammatory response cause a pathology, and why not in another? With the recent knowledge we
Int. J. Mol. Sci. 2017, 18, 1438 4 of 13
have gained, we have began to look for new keys in this process and to try to obtain an answer within
this new family of receptors known as PPARs.
2. Peroxisome Proliferator-Activated Receptors (PPARs) in Periodontitis as Inflammatory Disease
PPARs were originally identified in Xenopus frogs as receptors that induce the proliferation of
peroxisomes in cells. They are a group of nuclear receptor proteins regulating the expression of genes.
Three types of PPARs have been identified: α, γ, β/δ. PPARα is expressed in expressed in liver, kidney,
heart, muscle, and adipose tissue. PPARγ is expressed in all tissues. PPARβ/δ is strongly expressed
in brain, adipose tissue and skin. They are key players in the regulation of cellular differentiation,
development, and metabolism (carbohydrate, lipid, protein), and tumor production [31]. Basically,
PPARs are considered as lipid sensors, that according to its availability leads to fatty acid metabolism
or lipid storage. Also, PPARs play a major role in inflammation. For instance, they are involved in
age-related inflammation, caloric restriction, and longevity [32]. Activation of PPARγ reduces the
inflammation and can be activated by some non-steroidal anti-inflammatory and oral antidiabetic
drugs. Many of PPARγ’s established anti-inflammatory effects have been shown to occur through
innate immune signaling, particularly in monocytes and macrophages, but new data is investigating
the role of PPARγ and its ligands (including thiazolidinediones, prostaglandins, and oleanolic acids)
in the resolution of inflammation [33]. Genetically modified mice showed that PPARα-impaired
activity results in a modified inflammatory reaction, which causes a temporary delay in epidermal
healing [34]. The upregulation of PPARβ/δ expression and endogenous agonist is triggered by tumor
necrosis factor-α (TNF-α), a proinflammatory cytokine [35]. The antiinflammatory role of PPARβ/δ
has been related to the utilization of agonists in different models of neurodegenerative diseases [36].
In inflammatory bowel diseases, the activation of PPARα or PPARγ has antiinflammatory effects in the
intestine, decreasing the production of inflammatory markers and slowers the progression of colitis [37].
PPARα is the molecular target of the fibrates class of drugs, such as fenofibrate, which act as agonistic
ligands of PPARα [38]. Also, PPARα ligands can inhibit the expression of various proinflammatory
genes, such as interleukin (IL)-6, vascular cell adhesion molecule-1, platelet-activating factor (PAF)
receptor and cyclooxygenase (COX)-2 generating prostaglandin E2 (PGE2) and thromboxane B2 (TxB2),
in response to cytokine activation [39].
On the whole, PPARs ligands activate PPARs to express their target genes. These agonists can be
synthetic molecules, such as anti-hypertriglyceridemia drugs and insulin resistance, or fatty acids and
eicosanoids. The first synthetic high-affinity ligand for PPARβ/δ is the GW0742; it can modulate the
inflammatory process and could limit the development of periodontitis. It has been demonstrated in
rats to result in a substantial reduction of ligature-induced periodontitis, reducing plasma extravasation
and the degree of bone resorption. Therefore, it could provide a promising approach for the treatment
of periodontitis, reducing plasma extravasation and the bone resorption during periodontitis [40].
At present, therapy with mesenchymal stem cells (MSC) is one of the most promising options to
treat some diseases. Periodontal ligament stem cells have emerged as readily available therapeutic
sources. They share core MSC properties such as colony formation and multipotential differentiation
abilities, and may be ideal for repairing periodontal defects and achieving tooth regeneration with
fewer drawbacks. Real-time PCR shows a highly elevated level of PPARγ in these cells [41]. One of
the main bacteria involved in periodontitis is Porphyromonas gingivalis, and its lipopolysaccharide
(LPS) induce the expression of inflammatory cytokines TNF-α, IL-1β, and IL-6 and chemokines
IL-8 in human gingival fibroblasts (HGF) [42]. The activation of PPARγ could inhibit LPS-induced
inflammatory response [43] (Figure 2). A major metabolite of anthocyanins, the protocatechnic
acid, inhibit LPS-induced inflammation, suppressed IL-6 and IL-8 production in LPS-stimulated
HGF and can be reversed by the PPARγ antagonist GW9662 [44]. The evidence that rosiglitazone
(RGZ), a PPARγ agonist, reduces acute and chronic inflammation has been tested in a rat model of
periodontitis. It demonstrated a reduction in the development of periodontitis, the presence in the
mucogingival tissues with polymorphonuclear cells, the degree of nitrotyrosine formation and the
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level of injury in mucogingival tissues. All these findings support an attenuation of the damage
produced in experimental periodontitis [45]. The interaction between PPARγ gene polymorphism with
periodontal disease has been studied in some papers without a clear conclusion. The association of five
polymorphisms (rs10865710, rs2067819, rs3892175, rs1801282, rs3856806) within the PPARG gene with
chronic periodontitis was studied in a group of patients aged from eight to 85 years-old. The results
show that none of the haplotypes was significantly different between the periodontitis and healthy
controls. Therefore, it could not demonstrate a significant association between PPARG gene variants
and chronic periodontitis [46]. In a group of pregnant women (the average age of the subjects being
approximately 31 years-old), it could not be demonstrated an association between the PPARγ Pro12Ala
polymorphism and the presence of periodontitis because they did not reach statistical significance [47].
Later the same group of authors showed a significant association with periodontal disease in obese
elderly females, indicating a gene–gene or gene–environmental interaction among periodontal disease
and each gene polymorphism [48]. Another study made in a group of postmenopausal women with
slight periodontitis do not demonstrate any independent associations between the PPARγ Pro12Ala
polymorphism and any of the periodontal clinical parameters [49].
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Figure 2. Anti-inflammatory effect of peroxisome proliferator-activated receptors γ (PPARγ). A rat 
model of ligature-induced periodontitis shows the effects of WY14643, a potent peroxisome 
proliferator activator receptor α (PPARα) agonist. The treatment with WY14643 attenuates the degree 
of inflammatory response in the gingival tissues. All of these data support that PPARα has a 
pernicious role in the development of damage associated with periodontitis in rats [50]. TNF-α, tumor 
necrosis factor-α; IL-1β, interleukin 1 β; IL-6, interleukin 6; IL-8, interleukin 8; and LPS, 
lipopolysaccharide. 
3. PPARs in Periodontitis as Bone Disease 
The balance of bone metabolism is supported by osteoclast-induced bone resorption and 
osteoblast-induced bone formation. Osteoblastic lineage cells and activated T lymphocytes produce 
a receptor activator of nuclear factor (NF-κB) ligand (RANKL). It is the essential factor for osteoclast 
formation, fusion, activation, and survival, resulting in bone resorption and bone loss. RANKL has a 
specific receptor located on osteoclast and dendritic cells: RANK. The activation of RANK promotes 
the signaling cascade including stimulation of the c-jun, NF-κB, and protein serine/threonine kinase 
(PKB/Akt) pathways. The effects of RANKL are counteracted by osteoprotegerin (OPG) which acts 
as a soluble neutralizing receptor. The regulation of RANKL and OPG are mediated by cytokines 
(tumor necrosis factor α, interleukins 1, 4, 6, 11, and 17), various hormones (glucocorticoids, vitamin 
Figure 2. Anti-inflammatory effect of peroxisome proliferator-activated receptors γ (PPARγ). A rat
model of ligature-induced periodontitis shows the effects of WY14643, a potent peroxisome proliferator
activator receptor α (PPARα) agonist. The treatment with WY14643 attenuates the degree of
inflammatory response in the gingival tissues. All of these data support that PPARα has a pernicious
role in the development of damage associated with periodontitis in rats [50]. TNF-α, tumor necrosis
factor-α; IL-1β, interleukin 1 β; IL-6, interleukin 6; IL-8, interleukin 8; and LPS, lipopolysaccharide.
3. PPARs in Periodontitis as Bone Disease
The balance of bone metabolism is supported by osteoclast-induced bone resorption and
osteoblast-induced bone formation. Osteoblastic lineage cells and activated T lymphocytes produce a
receptor activator of nuclear factor (NF-κB) ligand (RANKL). It is the essential factor for osteoclast
formation, fusion, activation, and survival, resulting in bone resorption and bone loss. RANKL
has a specific receptor located on osteoclast and dendritic cells: RANK. The activation of RANK
promotes the signaling cascade including stimulation of the c-jun, NF-κB, and protein serine/threonine
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kinase (PKB/Akt) pathways. The effects of RANKL are counteracted by osteoprotegerin (OPG)
which acts as a soluble neutralizing receptor. The regulation of RANKL and OPG are mediated by
cytokines (tumor necrosis factor α, interleukins 1, 4, 6, 11, and 17), various hormones (glucocorticoids,
vitamin D, estrogen), and several mesenchymal transcription factors (such as Cbfa-1, peroxisome
proliferator-activated receptor γ, and Indian hedgehog).
Stimulation of PPARγ induces the development of mesenchymal stem cells into adipocytes
instead of osteoblasts and results in the decrease of the number of osteoblasts and bone mineral
density (BMD). PPARγ gene polymorphisms have been reported to be associated with bone loss and
osteoporosis [51]. A study showed that PPARγ also functions as an essential modulator of osteoclast
differentiation. Mice with PPARγ-deficiency in their hematopoietic lineage cells are osteopetrotic as a
result of impaired c-Fos expression. These data suggest that PPARγ acts as an important regulator
of c-os expression [52]. Another study demonstrates that the activation of liver X receptor (LXR)
attenuated the PPARγ agonist-induced c-Fos expression, and the ectopic expression of LXR suppressed
PPARγ-induced Activator protein 1 (AP-1) promoter activity. LXR can be identified as a negative
regulator of PPAR-mediated induction of c-Fos and transactivation of AP-1 in the context of osteoclast
development. The authors propose that LXR agonists may be of value in the treatment of bone-erosive
diseases characterized by increased osteoclast number [53].
Mechanical loading is essential in the maintenance of bone mass and structures around the
teeth and bone physiology. Some papers indicate that the mechanical loading of osteoblasts
produces the expression of transcription factor PPARγ-1 mRNA. The coordinated synthesis of
∆12PGJ2, a natural ligand for PPARγ-1, with the increased expression of PPARγ-1, point out that
the biomechanical transduction pathways that initially involve the activation of cyclooxygenases
may also require the activation of the ∆12PGJ2–PPAR pathway [54]. These data also suggest that
prostaglandin (PGD2) biosynthesis induced in bone cells by mechanical stress may be one of the
major inducers of osteogenesis. The same group of authors investigated the molecular events
produced in osteogenesis secondary to mechanical loading and ∆12PGJ2, namely the induction of
bone morphogenetic proteins and peroxisome proliferator-activated receptor γ-1, a nuclear receptor
for ∆12PGJ2. Mechanical strain increased the mRNA expression of peroxisome proliferator-activated
receptor γ-1. In stretched cells, bone peroxisome proliferator-activated receptor γ-1 expression was
blocked by cyclooxygenase inhibitors, but improved by exogenous ∆12PGJ2. These data suggest that
the ∆12PGJ2/peroxisome proliferator-activated receptor γ-1 is essential in osteogenesis [55]. The effect
of ∆12PGJ2 on periodontitis inhibited the production of interleukin-6 (IL-6) in osteoblast-like cells
MC3T3E-1 incubated with LPS. Data showed that it is an effective inhibitor of the LPS-stimulated
IL-6 production, in a dose-dependent manner, through the blockade of NF-κB and the Akt pathway.
These data suggest a possible mechanism responsible for its anti-inflammatory action and the use as a
therapeutic drug for treating LPS-stimulated periodontal diseases [56].
A relationship between osteoporosis and periodontal conditions has been studied. Systemic
bone density and oral infection, analyzed in the presence of a periodontal bacteria such as Tannerella
forsythensis, was found to modify oral bone loss in post-menopausal women aged <70 years [57]. In a
group of 400 postmenopausal women, osteoporosis was significantly associated with severe alveolar
crestal bone loss and the prevalence of periodontitis cases [58]. Another paper showed data from
90 women aged 45–70 years; the osteoporotic women presented severe periodontitis with greater
gingival inflammation, greater clinical attachment level and greater gingival recession than the women
with normal BMD [59]. A group of 179 male and female patients were divided into an osteopenia,
and a non-osteopenia group and a follow-up clinical surveys were done by measuring periodontal
conditions after 3 years. BMD was related to the number of progressive sites which had additional
attachment loss during the observational period [60].
Pathogenic bone resorption occurring in periodontal disease is known to be produced
by inflammation, PPARγ activation can downregulate the bone resorption mediated by
RANKL-dependent osteoclastogenesis. RGZ, a high-affinity synthetic agonist for PPARγ, influences the
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bone resorption induced in rats by experimental periodontitis caused by ligature placement around the
tooth. Histological and immunohistochemical analysis showed that the treatment with RGZ decreased
bone resorption, alongside reduced RANKL expression, in contrast to those animals treated with empty
vehicles. Also, along with these results obtained from in vivo experiments, RGZ also suppressed
in vitro osteoclast differentiation in the presence of RANKL in mouse monocyte/macrophage
(MOCP-5) osteoclast precursor cells, and the downregulation of the expression of RANKL-induced
TRAP mRNA. So, RGZ might suppress the bone resorption by inhibiting RANKL-mediated
osteoclastogenesis obtained during experimental periodontitis in rats [61].
A study investigated the potential associations between the PPARγ Pro12Ala polymorphism,
periodontitis and bone mineral density (BMD) in 674 women between the ages of 55 and 74 years-old.
The association between BMD or periodontitis and PPARG Pro12Ala polymorphism was not
independent. The common point could be in the modulator role of the polymorphism in this
relationship [62].
In dentistry, the treatment with implants involved the bone integration of the titanium surface
without any inflammation. Some papers have been proposed to deliver antiinflammatory molecules
PPARγ on titanium surfaces using chitosan gold nanoparticles (Ch-GNPs). They evaluated the protein
levels of TNF-α and IL-1β in RAW 264.7 cells. Expression of these cytokines was not observed in
cells cultured on Ch-GNPs/PPARγ-coated titanium surfaces. But, upregulation of pro-inflammatory
cytokines was detected on non-coated and Ch-GNPs/LacZ-coated titanium surfaces. These data
suggested that the Ch-GNPs/PPARγ coated titanium surfaces could carry the anti-inflammatory gene
and inhibit inflammation [63].
4. PPARs in Periodontitis and Its Related Systemic Diseases
We have shown that periodontitis is related to some systemic diseases such as cardiovascular
disease produced by atherosclerosis, diabetes mellitus, and metabolic syndrome. The pathophysiology
of these diseases share a common background of low-grade modified inflammation. Periodontitis
results from an imbalance of the bacteria and the host inflammatory response that produce an
irreversible alveolar bone resorption, leading to tooth loss. Nowadays, the key question is why
in some patients, the inflammation is limited to gingivitis as a reversible disease, and in others
produces periodontitis with an irreversible alveolar bone loss. One of the possible mechanisms is an
impaired inflammatory response. We have proposed that the interrelationship could lie at a cellular
level, namely oxidative stress and mitochondrial dysfunction, as a meeting background among such
chronic diseases and periodontitis [64]. Also, all the periodontitis-related systemic diseases show in
its pathogenic mechanism an altered inflammation associated with an excessive caloric intake and
increased or inadequate free fatty acid intakes [65]. Even the origins of susceptibility for these diseases
in the adult can be identified to the early life, early-life nutrition plays an essential role in placental and
fetal growth, organogenesis, and development [66]. PPARs contribute to the plasticity of the placenta
and are under epigenetic control; it has been proposed there is a relationship between environmental
factors, such as maternal nutrition, and the epigenetic regulation of PPRs [67]. Glucose and related
sugars, lipids, and amino acids are essential nutrients. The control of the above environmental nutrient
levels is essential for life; it is controlled by nutrient-sensing mechanisms and pathways. One of
them is PPARs; they are nutrient-sensing nuclear receptors with integrators activity in metabolic
responses [68].
Metabolic syndrome is defined as the combination of multiple metabolic disorders, including
obesity, dyslipidemia, glucose intolerance, inflammation, and hypertension. Low-grade inflammation
is a common background between insulin resistance, obesity and type-2 diabetes [65]. In recent years,
some studies showed that PPARs could improve several of the metabolic abnormalities associated
with the metabolic syndrome [69].
Specific genetic polymorphisms have been associated with a susceptibility to obesity. Expression
of these susceptibility genes can be modified by epigenetic and environmental factors. Diet and
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nutritional status can affect the transcription factors and microRNAs (miRNAs) regulatory systems.
Evidence from in vitro studies and from human studies has identified specific miRNAs associated with
obesity. miRNAs are small, non-coding RNA molecules that bind and form complexes with mRNA
species, namely to the 3’UTR of the mRNA [70]. miRNAs regulate adipocyte development and lipid
metabolism. Expression of miR-27 suppresses the translation of peroxisome proliferator-activated
receptor-γ (PPARγ) and is an essential early regulator of adipogenesis [71]. miR-143 expression is
upregulated 3.3-fold in obese mice, and increases the adipocyte differentiation markers PPARγ and the
adipocyte fatty-acid-binding protein [72]. PPARγ also regulates adipogenesis, and its polymorphisms
have been suggested to be a risk for obesity. Body mass index (BMI) has been associated with
Pro12Ala polymorphism [73]. Also, it was studied whether the Pro12Ala polymorphism of peroxisome
proliferator-activated receptor γ (PPARγ) is related to insulin resistance, obesity, and weight loss
and the potential interactions between fat intake and PPARγ polymorphism was explored. Data
showed a protective role for the Ala12 allele against insulin resistance, and the interaction between
dietary monounsaturated fatty acids (MUFA) and PPARγ2 for BMI [74]. PPARγ increased the plasma
adiponectin concentration and is suggested as a therapeutic tool through the dietary regulation
by derivatives of its active compounds, such as vitamins, polyunsaturated fatty acids (PUFA) or
carotenoids [75].
The relationship between cardiovascular disease and PPAR has been reported. PPARβ/δ ligands
and the overexpression of this nuclear receptor inhibits myocardial inflammatory responses, such
as the lipopolysaccharide-mediated production of TNF-α. This had positive effects on animals that
had undergone an ischemia/reperfusion injury or cardiac hypertrophy [76]. PPARβ/δ ligands are
capable of improving cardiac function, and can even enhance some cardiac diseases such as heart
failure, oxidative damage, hypertrophy, ischemia–reperfusion injury, lipotoxic cardiac dysfunction and
lipid-induced cardiac inflammation [77].
The pathophysiology of diabetes includes an important inflammatory aspect. PPARα is essential
in the dysregulation of inflammation. PPARα protein level was examined by immunohistochemistry
in type-2 diabetic Goto-Kakizaki rats with induced periodontitis. The results showed the number
of gingival fibroblast with PPAR-α protein was low at baseline and then in both, normoglycemic
and diabetic rats with ligature-induced periodontitis. When the ligature was removed and the
periodontitis solved, the normoglycemic rats presented a threefold increase in the relative expression
of PPARα. On the contrary, no change was observed in the diabetic animals. However, diabetic rats
treated with TNF-inhibitor, showed a significant increase, so that the diabetic rats with TNF-inhibitor
function similarly to the normal animals. Thus, PPARα could participate in the resolution of
periodontitis through its antiinflammatory properties, but under diabetic conditions, its upregulation
is restrained [78].
The role of monocytes and macrophages in diabetic periodontal diseases has been investigated;
the results indicated that monocytes and macrophages are important players in periodontal tissue
inflammation and destruction in diabetic patients. Monocytes isolated from diabetic patients produce a
greater amount of TNF-α and interleukin-1β in vitro than do nondiabetic controls [79]. A high glucose
content markedly increased lipopolysaccharide-induced inflammatory cytokine and inducible nitric
oxide synthase (iNOS) expression in U937 macrophages. These data indicated that hyperglycemia
in diabetic patients may boost the inflammatory response leading to increased cytokine release.
An antidyslipidemic drug, fenofibrate, increased lipopolysaccharide, induced TNF-α secretion and
an antidiabetic drug, pioglitazone; increased lipopolysaccharide-induced TNF-α, interleukin-1β, and
interleukin-6 secretion. But, pioglitazone and fenofibrate do not inhibit the stimulatory effect of high
glucose and lipopolysaccharide on the secretion of pro-inflammatory cytokines effectively, but only if
it suppressed by statin [80].
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5. Conclusions
In the complex process involving inflammatory diseases such as periodontal disease,
cardiovascular disease, diabetes and metabolic syndrome, PPARs could play an important role and give
new clues to a better therapeutic approach. PPARs are the molecular targets of a number of marketed
drugs. We should use those to prevent or treat periodontal diseases. This is our new challenge.
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